PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 is an effective inhibitor of inhaled p38 MAPK. PF-03715455 displays some selectivity for p38α over p38β (respective IC50: 0.88 and 23 nM). PF-03715455 has the potential for the treatment of COPD.

PF-03715455 is a moderate inhibitor of CYP1A2, CYP2C19, and CYP2D6. It also is an effective inhibitor of CYP's 2C9 and CYP3A4[2].

PF-03715455 treatment displays that the Vss is 0.19 L/kg and T1/2 is 1 hour [2].

1056164-52-3

C35H34ClN7O3S2

700.27

PF-03715455

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years